TNGXNasdaqPharmaceutical PreparationsUS GAAP · USD

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. is a U.S.-based precision oncology company focused on discovering and developing targeted cancer therapies for genetically defined patient populations. Its pipeline centers on small-molecule drug candidates designed to selectively attack cancer cells with specific genetic alterations while sparing normal cells.

Kysy yhtiöstä
Liikevaihto62,4milj. USD
+48,3 %v/v
Liikevoitto (EBIT)−111milj. USD
+23,6 %v/v
EBIT-marginaali−178,4%
+167,7 %-yks.v/v
Nettotulos−102milj. USD
+22,0 %v/v
Vapaa kassavirta−140milj. USD
−5,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−150−100−50050100milj. USD2020: 7,7 milj. USD2020: EBIT −52 milj. USD20202021: 37 milj. USD2021: EBIT −58 milj. USD20212022: 25 milj. USD2022: EBIT −111 milj. USD20222023: 37 milj. USD2023: EBIT −114 milj. USD20232024: 42 milj. USD2024: EBIT −146 milj. USD20242025: 62 milj. USD2025: EBIT −111 milj. USD202562−111
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Clinical-stage oncology programs80 %

Drug candidates in human clinical development for genetically defined cancers.

Collaboration revenue20 %

Revenue recognized from partnered research and licensing arrangements.

Target discovery platform0 %

Internal discovery capabilities used to identify disease-relevant oncology targets.

Tuotteet

Raportoitu · osuus liikevaihdosta
71,2%28,8%FY2024100 %
  • Collaboration Revenue71,2 %
  • License Revenue28,8 %

Lähde: 10-K FY2024, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Tango Therapeutics does not sell commercial products today; its economic counterparties are pharmaceutical collaborators, research partners, and future oncology patients through regulated drug development. In the current model, revenue is primarily tied to collaboration agreements, while the eventual commercial customer base would be hospitals, oncologists, and payors if product candidates are approved.

Pharmaceutical collaboration partners

Buy access to discovery, research, and licensing rights in oncology programs.

Future oncology treatment providers

Hospitals, cancer centers, and oncologists that would use approved therapies.

Payers and reimbursement decision-makers

Assess clinical value and coverage for any approved cancer medicines.

Research and translational science partners

Support target validation, biomarker work, and early-stage development.

Strategia

Tango Therapeutics is focused on advancing genetically targeted oncology programs through clinical proof-of-concept and biomarker-driven development. Its strategy relies on selecting cancer vulnerabilities such as MTAP deletion and building differentiated small molecules that can be paired with combination regimens or used in CNS settings.

Advance vopimetostat and TNG456 in clinical developmentLyhyt aikaväli

Clinical validation is the main path to value creation for a pre-commercial oncology company.

Differentiate through genetically defined patient selectionKeskipitkä aikaväli

Targeting MTAP-deleted tumors can improve selectivity and clinical relevance.

Expand combination and CNS opportunitiesKeskipitkä aikaväli

Combination regimens and brain-penetrant assets broaden the addressable oncology market.

Preserve access to external funding and partnershipsLyhyt aikaväli

The company depends on collaboration revenue and capital markets to finance development.

Maantiede

The company is headquartered in the United States and conducts its core research and development activities from Boston, Massachusetts. Its operational footprint also depends on third-party manufacturing and clinical supply chains, including a supplier located in China, which creates geographic exposure in both development execution and supply continuity.

Riskit

The company faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory approval risk, and the need for substantial external funding before any product sales. It also has meaningful supply-chain concentration, including single-source or limited-source API and drug-product manufacturing, and its oncology programs face intense competition from other PRMT5 and precision oncology developers.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical development failure1Capital dependence2Manufacturing and supply concentration3China-related supply chain exposure4Competitive pressure in oncology5Pricing and reimbursement risk6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea

    Pipeline value depends on demonstrating safety and efficacy in human trials.

    KohdistuuVopimetostatTNG456TNG260
  2. Capital dependenceVaikutus: KorkeaTodennäköisyys: Korkea

    The company must fund long-duration R&D before product revenue exists.

    KohdistuuEquityDebtCollaboration financing
  3. Manufacturing and supply concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen

    API and drug product rely on a small number of third-party suppliers.

    Kohdistuu: Clinical trial supply and future commercial supply

  4. China-related supply chain exposureVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    One CDMO is located in China, creating geopolitical and logistics risk.

    Kohdistuu: API and drug product sourcing

  5. Competitive pressure in oncologyVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Other companies are developing PRMT5 and related precision oncology programs.

    Kohdistuu: PRMT5 inhibitor market and broader oncology pipeline

  6. Pricing and reimbursement riskVaikutus: KeskitasoTodennäköisyys: Matala

    Future approved therapies may face coverage limits and pricing pressure.

    Kohdistuu: U.S. and ex-U.S. commercialization

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition for collaborations

Gilead-style agreements may include upfront, extension, milestone, and royalty elements.

Vaikutus: Affects timing and volatility of reported revenue

Deferred revenue

Upfront collaboration consideration may be recognized over future periods.

Vaikutus: Can materially shift revenue between quarters and years

Contingent milestone and royalty obligations

Future payments depend on development, regulatory, and commercial events.

Vaikutus: Affects future expense recognition and cash outflows

Lease accounting

Office and laboratory leases create operating lease liabilities and ROU assets.

Vaikutus: Affects balance sheet leverage and operating expense presentation

Clinical trial and manufacturing accruals

Third-party CRO and CDMO services require estimates for work performed but not billed.

Vaikutus: Can affect R&D expense timing and comparability

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

Sangamo Therapeutics, Inc

SGMOQ · Biological Products, (No Diagnostic Substances)

Cero Therapeutics Holdings, Inc.

CEROW · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026